Savara Inc.

NasdaqGS:SVRA 株式レポート

時価総額:US$576.6m

Savara マネジメント

マネジメント 基準チェック /24

Savaraの CEO はMatt Paulsで、 Sep2020年に任命され、 の在任期間は 4.17年です。 の年間総報酬は$ 3.76Mで、 15.8%給与と84.2%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.3%を直接所有しており、その価値は$ 1.71M 。経営陣と取締役会の平均在任期間はそれぞれ3.2年と7.6年です。

主要情報

Matt Pauls

最高経営責任者

US$3.8m

報酬総額

CEO給与比率15.8%
CEO在任期間4.2yrs
CEOの所有権0.3%
経営陣の平均在職期間3.2yrs
取締役会の平均在任期間7.6yrs

経営陣の近況

Recent updates

Savara: Trial Successful, But I'm Only Half Convinced

Sep 09

Savara: Today's Data 'Win' Rouses Market All Too Briefly

Jun 26

Savara: The Binary Bet On Phase 3 Data

Jun 07

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

Dec 14
Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Feb 16
Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Oct 12
Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Aug 26

Savara GAAP EPS of -$0.06 in-line

Aug 11

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Jan 24
Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Is Savara (NASDAQ:SVRA) A Risky Investment?

Jul 05
Is Savara (NASDAQ:SVRA) A Risky Investment?

Savara: They Failed Once, But They Are Trying Again

Jun 07

The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Mar 17
The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Feb 26
Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex

Nov 24

Savara EPS misses by $0.01

Nov 05

CEO報酬分析

Savara の収益と比較して、Matt Pauls の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$83m

Jun 30 2024n/an/a

-US$75m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$4mUS$595k

-US$55m

Sep 30 2023n/an/a

-US$49m

Jun 30 2023n/an/a

-US$43m

Mar 31 2023n/an/a

-US$40m

Dec 31 2022US$2mUS$580k

-US$38m

Sep 30 2022n/an/a

-US$39m

Jun 30 2022n/an/a

-US$39m

Mar 31 2022n/an/a

-US$41m

Dec 31 2021US$2mUS$560k

-US$43m

Sep 30 2021n/an/a

-US$45m

Jun 30 2021n/an/a

-US$46m

Mar 31 2021n/an/a

-US$44m

Dec 31 2020US$2mUS$170k

-US$50m

Sep 30 2020n/an/a

-US$68m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$81m

Dec 31 2019US$64kn/a

-US$78m

Sep 30 2019n/an/a

-US$57m

Jun 30 2019n/an/a

-US$57m

Mar 31 2019n/an/a

-US$47m

Dec 31 2018US$114kn/a

-US$62m

Sep 30 2018n/an/a

-US$58m

Jun 30 2018n/an/a

-US$52m

Mar 31 2018n/an/a

-US$53m

Dec 31 2017US$75kn/a

-US$31m

報酬と市場: Mattの 総報酬 ($USD 3.76M ) は、 US市場 ($USD 2.14M ) の同規模の企業の平均を上回っています。

報酬と収益: Mattの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Matt Pauls (53 yo)

4.2yrs

在職期間

US$3,759,723

報酬

Mr. Matthew Pauls, J.D. M.B.A. also known as Matt, is Director at NVN Liquidation Inc. He serves as Director of Soleno Therapeutics, Inc. since August 15, 2023 and is its Lead Independent Director aince Au...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Matthew Pauls
Chairman & CEO4.2yrsUS$3.76m0.30%
$ 1.7m
David Lowrance
CFO, Chief Administrative Officer & Secretary8yrsUS$1.52m0.048%
$ 276.7k
Robert Lutz
Chief Operating Officer1.8yrsUS$2.66m0%
$ 0
Kate McCabe
Senior VP & General Counsel6.7yrsデータなしデータなし
Anne Erickson
Chief Business Officer4.1yrsデータなし0.069%
$ 396.3k
Brian Maurer
Head of Clinical Operations3.5yrsデータなしデータなし
Charles LaPree
Senior Vice President of Global Regulatory Affairs & Quality Assurance3.3yrsデータなしデータなし
Peter Clarke
Executive Vice President of Global Technical Operations3.2yrsデータなしデータなし
Raymond Pratt
Chief Medical Officer2yrsUS$698.69k0.064%
$ 369.7k
Scott Wilhoit
Executive Vice President of Global Commercial1.8yrsデータなしデータなし
Brian Robinson
Senior VP of Global Medical Affairs1.6yrsデータなしデータなし
Yasmine Wasfi
Executive VP and Head of Clinical Development & Clinical Operationsless than a yearデータなしデータなし

3.2yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: SVRAの経営陣は 経験豊富 であると考えられます ( 3.2年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Matthew Pauls
Chairman & CEO7.6yrsUS$3.76m0.30%
$ 1.7m
David Ramsay
Independent Director7.6yrsUS$158.13k1.35%
$ 7.8m
Joseph S. McCracken
Lead Independent Director11.1yrsUS$155.13k0.11%
$ 632.8k
Richard Hawkins
Independent Director14.1yrsUS$149.13k0.0074%
$ 42.8k
Nevan Elam
Independent Director15.8yrsUS$157.63k0%
$ 0
Bruce Trapnell
Member of Clinical Advisory Boardno dataデータなしデータなし
Francesco Bonella
Member of Clinical Advisory Boardno dataデータなしデータなし
Yoshikazu Inoue
Member of Clinical Advisory Boardno dataデータなしデータなし
An van Es-Johansson
Independent Director4.9yrsUS$155.63k0%
$ 0
Cormac McCarthy
Member of Clinical Advisory Board3.8yrsデータなしデータなし
Tisha Wang
Member of Clinical advisory Board1.8yrsデータなしデータなし

7.6yrs

平均在職期間

61.5yo

平均年齢

経験豊富なボード: SVRAの 取締役会経験豊富 であると考えられます ( 7.6年の平均在任期間)。